NCT04733430

Brief Summary

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
500

participants targeted

Target at P75+ for all trials

Timeline
47mo left

Started Apr 2020

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress61%
Apr 2020Apr 2030

Study Start

First participant enrolled

April 17, 2020

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

January 18, 2021

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 2, 2021

Completed
9.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2030

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2030

Last Updated

March 18, 2024

Status Verified

March 1, 2024

Enrollment Period

10 years

First QC Date

January 18, 2021

Last Update Submit

March 15, 2024

Conditions

Lung Cancer

Keywords

NGS Testing

Outcome Measures

Primary Outcomes (1)

  • NGS Testing

    To assess molecular biomarker testing and indicators of the quality of care in patients with lung cancer

    through study completion, an average of 5 years

Eligibility Criteria

Age18 Years - 125 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All unselected patients diagnosed with lung cancer at the research sites. The study is intended to commence at two sites in Vienna, with subsequent invitation of participation of other sites.

You may qualify if:

  • Informed consent
  • Histologically confirmed lung cancer
  • Age ≥ 18 years
  • Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Karl Landsteiner Institut für Lungenforschung und Pneumologische Onkologie

Vienna, 1160, Austria

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Georg-Christian Funk, MD

    2nd Medical Department with Pneumology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Georg-Christian Funk, MD

CONTACT

+43 1 4000-2203georg-christian.funk@gesundheitsverbund.at

Agnes Attoh, BSc

CONTACT

+43 1 4000-72203agnes.attoh@extern.gesundheitsverbund.at

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
PROSPECTIVE
Target Duration
3 Months
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 18, 2021

First Posted

February 2, 2021

Study Start

April 17, 2020

Primary Completion (Estimated)

April 1, 2030

Study Completion (Estimated)

April 1, 2030

Last Updated

March 18, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations

AU(1)